Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Shares of Incyte stock opened at $60.60 on Friday. The company has a 50-day simple moving average of $69.53 and a two-hundred day simple moving average of $70.04. Incyte has a 52-week low of $50. ...

“Spider-Man: Beyond the Spider-Verse,” the third entry in Sony’s animated web-slinging trilogy, will swing into theaters… in a few years. It’ll be released on June 4, 2027. “We know ...